• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

ICU Nursing Care of the Stroke Patient
Almost 25 years ago, in June 1996, the Food and Drug Administration (FDA) approved intravenous (IV) Alteplase as the only acute drug therapy for ischemic stroke. It remains the mainstay drug to date and revolutionized Neurology, Stroke, and Neurocritcal Care. In 2013, the success of several mechanical thrombectomy studies proved the efficacy of endovascular thrombectomy for large vessel occlusions (LVO), both alone and in combination with IV Alteplase. The expanded time window opened this treatment option to a greater number of patients, who are now surviving with fewer deficits.
Source: Critical Care Nursing Clinics of North America - February 1, 2020 Category: Nursing Authors: Mary P. Amatangelo Tags: Preface Source Type: research

New Warning for the Multiple Sclerosis Drug Alemtuzumab
The Food and Drug Administration has added a black box warning for alemtuzumab (Lemtrada) stating that the drug, used in the treatment of relapsing multiple sclerosis, may cause ischemic and hemorrhagic stroke and cervicocephalic arterial dissection, rare but serious adverse effects.Nurses should teach patients prescribed this medication to recognize and seek emergency medical care if they develop any signs or symptoms of stroke.
Source: AJN - February 24, 2019 Category: Nursing Tags: Drug Watch Source Type: research

An Update on the Cardiovascular Risks Associated With NSAIDs
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used medications for osteoarthritis, rheumatoid arthritis, and myalgias (Table 1). In 2005, the United States Food and Drug Administration (FDA) placed a black box warning in the prescribing information of NSAIDs for the risk of myocardial infarction (MI) and stroke associated with their use.1 Last year, the FDA met to discuss new literature on NSAID cardiovascular (CV) risk to determine how it would affect prescription labeling.2 There were several observational studies and meta-analyses reviewed.
Source: The Journal for Nurse Practitioners - October 31, 2015 Category: Nursing Authors: Jason Babby, Archna Lall Tags: Prescription Pad Source Type: research

Managing Blunt Trauma in Patients Receiving Dabigatran Etexilate: Case Study and Review of the Literature
The objectives of this article are to present a case of life-threatening bleeding in a patient receiving dabigatran etexilate, followed by a review of the current literature and a suggested reversal guideline.
Source: Journal of Emergency Nursing: JEN - April 1, 2013 Category: Nursing Authors: Peter Eamonn Croft, Katherine P. Cabral, Tania D. Strout, Michael R. Baumann, Michael A. Gibbs, Matthew C. DeLaney Tags: Trauma Notebook Source Type: research

Implementing a Stroke Program Using Telemedicine
Stroke is the fourth leading cause of death and the leading cause of disability in the United States, affecting more than 750,000 people annually. Every 40 seconds someone experiences a stroke, and every 4 minutes a person dies from a stroke. In 1999 the American Heart Association (AHA), American Stroke Association (ASA), and the Brain Attack Coalition developed evidence-based guidelines for acute stroke care. These guidelines support the use of the antithrombotic drug tissue plasminogen activator (tPA) as a beneficial treatment for patients with acute stroke symptoms that meet specific guidelines. In the same year, the Fo...
Source: Journal of Emergency Nursing: JEN - July 2, 2012 Category: Nursing Authors: Tina Cronin Tags: Clinical Source Type: research